You searched for "entropion"

825 results found

Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions

The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Code-Free Deep Learning: a step into the future of ophthalmology

A new focus has arisen within the research domain of artificial intelligence (AI) in healthcare called code-free deep learning (CFDL), and recent research demonstrates that ophthalmology is becoming one of the leading specialties in this field. Artificial intelligence (AI) is...

Tackling diabetic retinopathy globally through the VISION 2020 LINKS Diabetic Retinopathy Network

It is abundantly clear that the burden of diabetes is rapidly increasing, as there are now 415 million adults with diabetes in the world, with a projected rise to 642 million by 2040 [1]. This equates to 1 in 10...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Implementing technology to improve global eye health

Technological innovation is providing new solutions to transform global eye health [1–5]. In particular, research towards the development of artificial intelligence (AI) tools in ophthalmology has gained pace in recent years. However, there has been little research relating to its...

The fragile p-value

Abdus Samad Ansari explores the limitation of the p-value and the application of the fragility index in clinical trials. Clinical trials and tribulations? The restoration of vision or more purely the gift of sight is an aspect of care that...

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Prevalence of acute anterior uveitis in diabetic patients attending diabetic eye disease clinics

The authors share their investigation at Manchester Royal Eye Hospital into the association between diabetes and AAU. The global prevalence of diabetes mellitus (DM) is rapidly rising from an estimated 9.3% in 2019 to 10.2% by 2030 [1]. The link...

Glaucoma: 30 years on

Back in 1993, the late and great Barry Cullen FRCS (Cavan born, Dublin trained), the first editor of Eye News, asked me to write an article about the current treatment of chronic open angle glaucoma (COAG). At the time I...

See sweet to C-suite: Peter Holland

See also - See sweet to C-suite: Imran Rahman In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part One: David speaks...